OLGX News Alert

Osteologix CEO to Present at Eye for Pharma Early Commercialization, Lifecycle and Portfolio Management Congress 2007
Wednesday October 24, 4:15 pm ET

October 25-26, Barcelo Sants Hotel, Barcelona

SAN FRANCISCO--(BUSINESS WIRE)--Osteologix Inc. (OTC BB: OLGX.OB) today announced that Philip J. Young, President and CEO of Osteologix, will give a presentation entitled, ?Pricing Considerations When Launching a Drug? to over 300 executive delegates at the Eye for Pharma Early Commercialization, Lifecycle and Portfolio Management Congress 2007 on October 25th at the Barcelo Sants Hotel in Barcelona, Spain. The presentation will address the complex issues of drug pricing once a company reaches the Launch stage of commercialization. Young brings to the table over twenty-five years of broad experience with biopharmaceutical development and commercialization. He has been the driving force behind numerous successful drug launches; including Nutropin? (Somatropin [rDNA origin] for injection) and Genotropin?(Somatropin [rDNA origin] for injection), for pediatric growth hormone deficiency, and Corlopam? (Fenoldopam Mesylate Injection, USP) for acute hypertensive episodes.. With a proven track record of success, Mr. Young is leading the development of Osteologix?s principal compound, NB S101, which is currently in Phase II clinical development for the treatment and prevention of osteoporosis. The company is set to release Phase II data in the fourth quarter of 2007.

About NB S101

Osteologix is developing NB S101, a once daily tablet containing strontium malonate, as a treatment for osteoporosis. The phase II study evaluating NB S101 is a randomized, double-blind, placebo-controlled, parallel-group efficacy and safety trial with the objective of assessing the effects of NB S101 on bone metabolism while also evaluating its safety, tolerability and pharmacokinetics in postmenopausal women. In addition to the primary endpoint of bone resorption, the company is evaluating the effects of NB S101 on bone formation and bone mineral density.

About Osteoporosis

Osteoporosis is the most common bone disease in humans and, according to the National Osteoporosis Foundation (NOF), 10 million Americans are estimated to have the disease and almost 34 million more are estimated to have osteopenia or low bone mass, placing them at increased risk for osteoporosis. The most severe consequence of osteoporosis is skeletal fracture. Osteoporosis is responsible for more than 1.5 million fractures annually and direct expenditures for hip fractures are estimated to cost society more than $18 billion annually. According to NOF, one in two women and one in four men over age 50 can be expected to have an osteoporosis-related fracture at some time.

About Osteologix

Osteologix is a specialty pharmaceutical company committed to developing innovative therapies for the treatment and prevention of musculoskeletal diseases. The Company?s vision is to improve the health of those afflicted with musculoskeletal diseases such as osteoporosis. Its lead product candidate, NB S101, is a novel pharmaceutical agent for the treatment and prevention of osteoporosis. For more information please visit www.osteologix.com.

For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com